Stay updated on Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial

Sign up to get notified when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Added a new record history entry 'Revision: v3.3.3' and removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' from the page footer. These are minor administrative updates that do not alter study information or how users interact with the page.
    Difference
    0.2%
    Check dated 2025-12-23T09:46:51.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    No Change Detected
  5. Check
    41 days ago
    Change Detected
    Summary
    The Record History now shows a new revision entry (v3.3.2) and omits the older entry (v3.2.0).
    Difference
    0.1%
    Check dated 2025-11-24T16:56:46.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Removed the government funding operating status notice from the page.
    Difference
    0.5%
    Check dated 2025-11-17T15:03:52.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    New version entry dated 2025-01-15 added to Record History, expanding the version chronology. This reflects the most recent submission and study record update.
    Difference
    0.1%
    Check dated 2025-11-03T01:32:17.000Z thumbnail image
  8. Check
    92 days ago
    Change Detected
    Summary
    Major update: publish of a funding-related operating status notice and a new software version (v3.2.0) replacing v3.1.0.
    Difference
    11%
    Check dated 2025-10-05T10:37:56.000Z thumbnail image
  9. Check
    99 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0; no substantive content changes detected.
    Difference
    0.3%
    Check dated 2025-09-28T03:23:53.000Z thumbnail image

Stay in the know with updates to Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.